← Executive Summary • Pillar 01: First-Principles Transduction & Biophysics
Signature Case Study 01 • Regulated Medical Computing

Clinical-Grade Physiological Intelligence
& 3 FDA 510(k) Clearances

Next Case Study →

How first-principles biophysical optics, Mie scattering models, and discrete wavelet signal processing delivered 3 FDA-cleared vital signs (K240236, K242224, and K254000)—culminating in the holy grail of digital health: continuous cuffless blood pressure monitoring.

Optical signals scattering through layered tissue and resolving into a physiological waveform
IN-VIVO OPTICAL TRANSDUCTION Layered Tissue Absorption, Discrete Wavelet Denoising & FDA 510(k) Clinical Verification
Executive TL;DR

Clinical Transduction & FDA Clearances

View 5 Pillars →
🎯 Business Context

Engineered clinical vital sign algorithms (heart rate, SpO2, sleep staging/apnea, and cuffless blood pressure) powering commercial wearable hardware with 3 FDA 510(k) clearances (K240236, K242224, K254000).

⚡ Technical Hurdle

Eliminating severe in-vivo motion artifacts and multi-spectral tissue scattering non-linearities to achieve calibration-free arterial compliance derivation under ISO 81060-2.

🏆 Deliverable & Impact

3 FDA 510(k) clearances (including cuffless BP K254000), 22 MedTech patents, and 99.8% beat-detection fidelity.

Leadership Scope Principal Data Scientist
Regulatory Outcome 3 FDA 510(k) Clearances
Standards Compliance ISO 81060-2 & IEC 62304
IP Footprint 22 MedTech Patents (6 Core Ring)

The Cuffless Blood Pressure Paradox

Continuous blood pressure monitoring has long been the "holy grail" of digital health. Traditional optical approaches rely on Pulse Transit Time (PTT) or purely data-driven black-box neural networks. However, these systems universally suffer from catastrophic calibration drift: a model calibrated on an individual today becomes inaccurate tomorrow due to changes in vascular tone, ambient temperature, motion artifacts, and skin pigmentation differences across demographics.

To achieve rigorous FDA 510(k) clearance under ISO 81060-2 clinical trial standards, the device algorithm could not rely on periodic user cuff re-calibration or uninterpretable statistical regressions. It required a calibration-free, first-principles mathematical model capable of disentangling optical absorption changes caused by blood volume expansion from background tissue scattering and motion noise in real time.

Multi-Spectral Tissue bed Modeling & Mie Scattering

Decomposing photonic interaction in heterogeneous dermal tissue into deterministic absorption and scattering equations.

Biophysical Optical Model Architecture
Inspect High-Resolution Diagram
Clinical AI & Biophysics

Tissue Vascular Bed Absorption & Isobestic Point Fitting

Multi-wavelength optical transduction isolating arterial pulse waves from venous baseline wander and tissue scattering.

By modeling the dermal tissue matrix through HPYTissueProperties, the algorithm tracks:

  • ✓
    Multi-Isobestic Point Wavelength Balancing: Leveraging multi-spectral optical channels (Blue, Green, Red, IR) where Blue provides high-resolution surface layer information while Red and IR penetrate deeper tissue beds where oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) extinction coefficients intersect, isolating volumetric pulse pressure from oxygenation fluctuations.
  • ✓
    Mie Scattering Separation: Deriving analytical solutions for photon pathlength variance in stratified epidermal layers to compensate for varying melanin concentrations and subcutaneous tissue depth.
  • ✓
    Dynamic Vascular Bed Compliance: Translating instantaneous optical pulse morphology into non-linear arterial compliance and peripheral vascular resistance metrics to enable calibration-free blood pressure estimation (FDA 510(k) Cleared: K254000).

Quantified Impact & Regulatory Milestones

3 Clearances
FDA 510(k) Official Approvals
K240236, K242224 & K254000
22 Patents
MedTech Patents
6 Core Ring Patents • 16 Biosensor/Clinical IP
FDA Cleared
Continuous Blood Pressure
K254000 • ISO 81060-2 Clinical Protocol Met